P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

• Sylvain Choquet,
• Andrew Clark,
• Cécile Renard,
• Ben Uttenthal,
• Sridhar Chaganti,
• Ralf Ulrich Trappe,
• Patrizia Comoli,
• Xinyuan Duan,
• Baodong Xing,
• Charley Wu,
• Laurence Gamelin,
• Jan-Henrik Terwey,
• Anke Friedetzky,
• Daan Dierickx

Affiliations

Sylvain Choquet

1 Hôpital de la Pitié-Salpêtrière, Paris, France

Andrew Clark

2 NHS Greater Glasgow and Clyde, Glasgow, United Kingdom

Cécile Renard

3 Institut d’Hématologie et d’Oncologie Pédiatrique, Lyon, France

Ben Uttenthal

4 Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom

Sridhar Chaganti

5 University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom

Ralf Ulrich Trappe

6 DIAKO Hospital Bremen, Bremen, Germany

Patrizia Comoli

7 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Xinyuan Duan

8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States

Baodong Xing

8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States

Charley Wu

8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States

Laurence Gamelin

8 Atara Biotherapeutics Inc, Thousand Oaks, CA, United States

Jan-Henrik Terwey

9 Atara Biotherapeutics Switzerland GmbH, Zug, Switzerland

Anke Friedetzky

9 Atara Biotherapeutics Switzerland GmbH, Zug, Switzerland

Daan Dierickx

10 University Hospitals Leuven, Leuven, Belgium